Jamshidi Maral, Fagerholm Rainer, Khan Sofia, Aittomäki Kristiina, Czene Kamila, Darabi Hatef, Li Jingmei, Andrulis Irene L, Chang-Claude Jenny, Devilee Peter, Fasching Peter A, Michailidou Kyriaki, Bolla Manjeet K, Dennis Joe, Wang Qin, Guo Qi, Rhenius Valerie, Cornelissen Sten, Rudolph Anja, Knight Julia A, Loehberg Christian R, Burwinkel Barbara, Marme Frederik, Hopper John L, Southey Melissa C, Bojesen Stig E, Flyger Henrik, Brenner Hermann, Holleczek Bernd, Margolin Sara, Mannermaa Arto, Kosma Veli-Matti, Van Dyck Laurien, Nevelsteen Ines, Couch Fergus J, Olson Janet E, Giles Graham G, McLean Catriona, Haiman Christopher A, Henderson Brian E, Winqvist Robert, Pylkäs Katri, Tollenaar Rob A E M, García-Closas Montserrat, Figueroa Jonine, Hooning Maartje J, Martens John W M, Cox Angela, Cross Simon S, Simard Jacques, Dunning Alison M, Easton Douglas F, Pharoah Paul D P, Hall Per, Blomqvist Carl, Schmidt Marjanka K, Nevanlinna Heli
Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, HUS, Finland.
Department of Clinical Genetics, University of Helsinki and Helsinki University Hospital, Helsinki, HUS, Finland.
Oncotarget. 2015 Nov 10;6(35):37979-94. doi: 10.18632/oncotarget.4991.
In breast cancer, constitutive activation of NF-κB has been reported, however, the impact of genetic variation of the pathway on patient prognosis has been little studied. Furthermore, a combination of genetic variants, rather than single polymorphisms, may affect disease prognosis. Here, in an extensive dataset (n = 30,431) from the Breast Cancer Association Consortium, we investigated the association of 917 SNPs in 75 genes in the NF-κB pathway with breast cancer prognosis. We explored SNP-SNP interactions on survival using the likelihood-ratio test comparing multivariate Cox' regression models of SNP pairs without and with an interaction term. We found two interacting pairs associating with prognosis: patients simultaneously homozygous for the rare alleles of rs5996080 and rs7973914 had worse survival (HRinteraction 6.98, 95% CI=3.3-14.4, P=1.42E-07), and patients carrying at least one rare allele for rs17243893 and rs57890595 had better survival (HRinteraction 0.51, 95% CI=0.3-0.6, P = 2.19E-05). Based on in silico functional analyses and literature, we speculate that the rs5996080 and rs7973914 loci may affect the BAFFR and TNFR1/TNFR3 receptors and breast cancer survival, possibly by disturbing both the canonical and non-canonical NF-κB pathways or their dynamics, whereas, rs17243893-rs57890595 interaction on survival may be mediated through TRAF2-TRAIL-R4 interplay. These results warrant further validation and functional analyses.
在乳腺癌中,已有报道称存在核因子-κB(NF-κB)的组成性激活,然而,该信号通路的基因变异对患者预后的影响鲜有研究。此外,基因变异的组合而非单个多态性可能会影响疾病预后。在此,我们利用乳腺癌协会联盟的一个大型数据集(n = 30431),研究了NF-κB信号通路中75个基因的917个单核苷酸多态性(SNP)与乳腺癌预后的关联。我们使用似然比检验探索SNP之间的相互作用对生存的影响,该检验通过比较有无相互作用项的SNP对的多变量Cox回归模型来进行。我们发现了两对与预后相关的相互作用:rs5996080和rs7973914的罕见等位基因同时纯合的患者生存情况较差(交互作用风险比6.98,95%置信区间=3.3 - 14.4,P = 1.42×10⁻⁷),而携带rs17243893和rs57890595至少一个罕见等位基因的患者生存情况较好(交互作用风险比0.51,95%置信区间=0.3 - 0.6,P = 2.19×10⁻⁵)。基于计算机模拟功能分析和文献,我们推测rs5996080和rs7973914位点可能通过干扰经典和非经典NF-κB信号通路或其动态变化,影响B细胞激活因子受体(BAFFR)和肿瘤坏死因子受体1/肿瘤坏死因子受体3(TNFR1/TNFR3)受体以及乳腺癌的生存,而rs17243893 - rs57890595对生存的相互作用可能通过肿瘤坏死因子受体相关因子2(TRAF2)-肿瘤坏死因子相关凋亡诱导配体受体4(TRAIL-R4)的相互作用介导。这些结果有待进一步验证和功能分析。